ClinicalTrials.gg
TerminatedNCT02756728Updated Mar 12, 2020

A Phase I/II Study of BI-505 in Conjunction With Autologous Stem Cell Transplant in Multiple Myeloma

A Phase 1/2 interventional study of BI-505 and High dose melphalan in Multiple Myeloma, sponsored by BioInvent International AB. Terminated at 1 site in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2020-03-12.

Sponsored by BioInvent International AB · Phase 1/2, Interventional, and Treatment

How we know

Why this study was terminated
Full clinical hold from FDA

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
5
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 2,168 studies in Multiple Myeloma with a site in United States — 273 open to participants now, 501 under way, 66 of them phase 3. Multiple Myeloma · United States.

Enrollment
1,716th of 1,901
5 · median 36
Started
2016
with 90 others
Phase 1/2
294 of 2,168
31 open now
Registered
1,289th of 2,168
by date

Among the 2,168 studies in Multiple Myeloma with a site in United States, this one is the 1,716th largest by enrollment of the 1,901 interventional ones that give a count, is one of 91 that started in 2016, is one of 294 in phase 1/2, and was the 1,289th registered.

Multiple Myeloma

3,764 studies on the registry are indexed under Multiple Myeloma; 768 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

273 of the 2,168 studies in Multiple Myeloma with a site in United States are open now. Recruiting first, the newest first:

268 more — sign in →

All 273 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 583 Multiple Myeloma studies recruiting now, 428 (73%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,168 studies in Multiple Myeloma with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to investigate the safety and efficacy of administering BI-505 in conjunction with high dose melphalan and stem cell transplantation in multiple myeloma patients.

Read the detailed description

N/A study is closed

03

Conditions studied

  • Multiple Myeloma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A diagnosis of multiple myeloma by 2014 IMWG criteria and have been recommended to undergo HDM + as a standard-of-care therapy for their multiple myeloma.
  • Subjects must have adequate vital organ function and functional status for HDM + ASCT
  • Subjects must have collected and cryopreserved ≥4x106 hematopoietic stem cells per kg of actual body weight that are suitable for use in autologous stem cell transplantation in the judgment of the investigator.
  • At the time of enrollment, subjects must have had at least a partial response, as defined by IMWG criteria and in comparison to baseline/pre-treatment parameters, to an induction regimen containing lenalidomide and/or bortezomib.
  • Subjects must have according to one of the following criteria:

    1. Serum M-spike ≥0.1 g/dl
    2. Urine M-spike >200 mg in a 24-hour urine collection
    3. Involved serum free light chain above the and a serum free light chain ratio outside the normal range.
  • At the time of enrollment, subjects must be within 12 months of the first dose of initial/induction therapy, and the anticipated day of ASCT must be within 12 months of the first dose of initial/induction therapy

Exclusion criteria

Exclusion Criteria:

  • Prior or autologous hematopoietic stem cell transplant
  • Current active infections, including and and B
  • disease requiring ongoing therapy.
  • History of atrial fibrillation or flutter, including paroxysmal atrial fibrillation or flutter.
  • History of or stroke.
  • At the time of enrollment, subjects must not have required multi-agent continuous-infusion cytotoxic chemotherapy (e.g., regimens such as D-PACE) as part of their initial/induction therapy.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
5 participants (actual)

Study arms

  • Active comparator
    HDM+ASCT

    Standard of care; High dose Melphalan + Autologous Stem Cell Transplantation

    Other: High dose melphalan · Other: Autologous stem cell transplantation

  • Experimental
    BI-505

    Biweekly infusions of BI-505 in addition to High dose Melphalan + Autologous Stem Cell Transplantation

    Biological: BI-505 · Other: High dose melphalan · Other: Autologous stem cell transplantation

Interventions

  • BiologicalBersanlimabStudies of BersanlimabBersanlimab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Treatment with BI-505 10 mg/kg bi-weekly infusion, up to 9 doses over 4 months

  • OtherHigh dose melphalan

    High dose melphalan (HDM)

  • OtherAutologous stem cell transplantation

    Autologous stem cell transplantation (ASCT)

06

What researchers measure

Primary outcomes

  1. Phase I: Determine the safety and feasibility of administering BI-505 in conjunction with HDM+ASCT in multiple myeloma patients

    UNK

    Time frame: Adverse events will be assessed within 30 days of ASCT in the safety part of the study.

  2. Phase II: Determine the effect of BI-505 on rate of stringent complete response for multiple myeloma patients with measurable disease pre-ASCT.

    UNK

    Time frame: At Day 100 after ASCT

Secondary outcomes

  1. Determine the effect of BI-505 on rate of stringent complete response (sCR) at day 100 in subgroups stratified according to response to initial therapy (+/- VGPR).

    UNK

    Time frame: Day 100 after ASCT

  2. Determine the effect of BI-505 administered in conjunction with HDM + ASCT on IMWG response category (PR, VGPR, CR, sCR) at one year post-ASCT and progression-free survival.

    UNK

    Time frame: At one year and up to three years after ASCT

  3. Evaluate the effect of BI-505 on MRD-negative rate at day 100 and change in MRD status at day 100 compared to baseline.

    UNK

    Time frame: Day 100

  4. Evaluate anti-myeloma effect of BI-505 monotherapy, prior to HDM + ASCT

    UNK

    Time frame: Prior to HDM + ASCT (from Day -17 until Day 0)

  5. Evaluate bone marrow immune cell composition and phenotype, including macrophage infiltration and expression of intracellular adhesion molecule (ICAM)-1 expression on multiple myeloma plasma cells, as potential biomarkers of response to BI-505

    UNK

    Time frame: Day 100 compared to Baseline (Day -17 and Day -2)

  6. Evaluate the pharmacokinetic profile of BI-505 in this clinical setting by analysing Cmax

    Maximum Plasma Concentration (Cmax)

    Time frame: All dosing visits throughout the study (up to 9 biweekly infusions of BI-505). Day -17, day -3, day 11, day 25, day 39, day 53, day 67, day 81, day 95, day 123

  7. Evaluate the pharmacokinetic profile of BI-505 in this clinical setting by analysing Tmax

    Time to reach Cmax (Tmax)

    Time frame: All dosing visits throughout the study (up to 9 biweekly infusions of BI-505). Day -17, day -3, day 11, day 25, day 39, day 53, day 67, day 81, day 95, day 123

  8. Evaluate the pharmacokinetic profile of BI-505 in this clinical setting by analysing AUC

    Area under the curve (AUC)

    Time frame: All dosing visits throughout the study (up to 9 biweekly infusions of BI-505). Day -17, day -3, day 11, day 25, day 39, day 53, day 67, day 81, day 95, day 123

  9. Evaluate the pharmacokinetic profile of BI-505 in this clinical setting by analysing CL

    Clearance (CL)

    Time frame: All dosing visits throughout the study (up to 9 biweekly infusions of BI-505). Day -17, day -3, day 11, day 25, day 39, day 53, day 67, day 81, day 95, day 123

  10. Evaluate the pharmacokinetic profile of BI-505 in this clinical setting by analysing Vss

    Volume of distribution at steady state (Vss)

    Time frame: All dosing visits throughout the study (up to 9 biweekly infusions of BI-505). Day -17, day -3, day 11, day 25, day 39, day 53, day 67, day 81, day 95, day 123

  11. Evaluate the pharmacokinetic profile of BI-505 in this clinical setting by analysing t1/2

    Elimination half-life (t1/2)

    Time frame: All dosing visits throughout the study (up to 9 biweekly infusions of BI-505). Day -17, day -3, day 11, day 25, day 39, day 53, day 67, day 81, day 95, day 123

07

Study locations

1 site
  • Perelman School of Medicine/Hospital of the Univ. of Pennsylvania/Abramson Cancer Center
    Philadelphia, Pennsylvania 19104, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2016 to primary completion in Dec 2016, 7 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 18, 2016
First posted
Apr 29, 2016
StartActual
May 2016
Primary completionActual
Dec 2016
CompletionActual
Dec 2016
Last update
Mar 12, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 12, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02756728
Lead sponsor
BioInvent International AB
Responsible party
Sponsor
First posted
Apr 29, 2016
Start date
May 2016
Primary completion
Dec 2016
Completion
Dec 2016
Last update
Mar 12, 2020

Study contacts

Alfred Garfall, MD
principal investigator · Div of Hema/Onc, Dept.of Med, Perelman Center Advanced Med, Philadelphia PA

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bersanlimab

Start the discussion